Vasopressin use in critically ill cirrhosis patients with catecholamine-resistant septic shock: The CVICU cohort

doi:10.4254/wjh.v9.i2.106

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 9, Issue 2

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8375)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-3) series.

Item

Count

PDF

441

WORD

309

HTML

3749

Figures (1-2)

160

Tables (1-3)

153

Sum=4812

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

497

Download

779

Sum=1276

Publishing Process of This Article

Item

Count

Browse

886

Download

1401

Sum=2287

Jan 18, 2017 (publication date) through Apr 19, 2024

Times Cited of This Article

Times Cited (8)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Hepatol. Jan 18, 2017; 9(2): 106-113
Published online Jan 18, 2017. doi: 10.4254/wjh.v9.i2.106

Table 1 Baseline patient characteristics

	Vasopressin (n = 21)	No Vasopressin (n =24)	P value
Patient demographics
Age, yr (95%CI)	56.2 (50.2-62.3)	57.0 (50.7-63.3)	0.681
Male gender	10 (47.6)	14 (53.9)	0.672
Body mass index, kg/m², (95%CI)	34.2 (30.5-37.9)	31.2 (28.0-34.3)	0.150
Comorbidities, n (%)
CAD	3 (14.2)	4 (16.7)	0.985
CHF	1 (5.3)	6 (23.1)	0.103
COPD	3 (16.7)	4 (16.7)	1.00
CKD	6 (28.6)	7 (29.2)	0.956
DM	7 (35.0)	8 (30.8)	0.762
HTN	13 (61.3)	16 (66.7)	0.916
Smoking, n (%)	5 (23.8)	5 (23.8)	0.756
Alcohol use (active), n (%)	9 (42.9)	8 (33.3)	0.392
Liver disease etiology, n (%)
Alcohol	6 (28.6)	10 (41.7)	0.477
NASH/crypto	5 (23.4)	7 (29.2)	0.240
HBV	0 (0.0)	0 (0.0)	1.00
HCV	3 (14.2)	3 (12.5)	0.566
Cardiac	1 (4.8)	1 (4.2)	0.947
Cholestatic	2 (9.5)	1 (4.2)	0.445
AIH	0 (0.0)	1 (4.2)	0.497
HCV/alcohol	3 (14.3)	1 (4.2)	0.329
PSE	14 (66.7)	15 (62.5)	0.927
Laboratory values and vital signs
MELD, (95%CI)	32.4 (28.6-36.2)	27.1 (23.6-30.6)	0.041
CTP, n (%)
A	0 (0.0)	0 (0.0)	1.00
B	2 (9.5)	6 (25.0)	0.074
C	19 (90.5)	18 (75.0)	0.162
AST, U/L, (95%CI)	429 (283-1141)	289 (90-667)	0.763
ALT, U/L, (95%CI)	180 (79-438)	133 (24-290)	0.795
Alk phos, U/L, (95%CI)	155 (109-200)	138 (90-185)	0.740
Bilirubin, mg/dL, (95%CI)	15.4 (9.0-21.9)	10.0 (5.3-14.6)	0.109
BUN, mg/dL, (95%CI)	58.0 (45.0-70.9)	48.7 (36.5-60.9)	0.222
Platelets, k/uL, (95%CI)	84.5 (66.2-102.8)	88.8 (68.9-108.8)	0.402
Creatinine, mg/dL, (95%CI)	3.02 (2.16-3.88)	2.50 (1.59-3.41)	0.37
GFR, mL/min per 1.73 m², (95%CI)	23.9 (18.6-29.2)	40.0 (29.1-51.0)	0.013
Sodium, mmol/L, (95%CI)	135.8 (131.8-139.8)	134.1 (130.8-137.5)	0.553
INR, (95%CI)	2.63 (1.79-3.48)	2.15 (1.82-2.47)	0.176
Hematocrit, %, (95%CI)	25.7 (22.9-28.6)	28.0 (26.1-30.0)	0.200
Lactate, mmol/L, (95%CI)	3.90 (2.58-5.21)	3.60 (2.52-4.68)	0.669
WBC (max), k/uL, (95%CI)	16.1 (12.8-19.5)	16.7 (12.7-20.6)	0.607
Heart rate, (95%CI)	106 (96-115)	110 (102-118)	0.591
MAP (min), (95%CI)	45.1 (34.2-56.1)	50.5 (46.9-54.0)	0.197
Temperature, C, (95%CI)	36.3 (35.5-37.1)	36.7 (35.9-37.4)	0.125
RR (max), breaths/min, (95%CI)	35.7 (30.5-40.8)	31.8 (25.4-38.3)	0.145
ICU level of illness, (95%CI)
FiO₂	0.48 (0.36-0.59)	0.44 (0.34-0.54)	0.953
PaCO₂	35.6 (32.7-38.5)	35.7 (32.1-39.3)	0.856
PaO₂	100.2 (49.1-151.4)	70.4 (60.2-80.6)	0.235
pH	7.30 (7.24-7.35)	7.34 (7.30-7.37)	0.149
APACHE II	33.5 (30.6-36.5)	31.8 (29.4-34.2)	0.306
GCS	7.1 (5.0-9.3)	6.9 (5.2-8.6)	0.547
SAPSII	72.6 (63.5-81.7)	70.3 (64.5-76.1)	0.975
SOFA	17.6 (15.9-19.3)	16.9 (15.9-18.0)	0.173
Average number of vasopressors	2.9 (2.4-3.3)	3.3 (2.9-3.6)	0.357
Days on vasopressors	6.3 (3.7-8.9)	6.3 (3.6-9.0)	0.756
CRRT/HD, n (%)	13 (65.0)	17 (70.8)	0.762
Intubated, n (%)	18 (85.7)	22 (91.7)	0.466
UOP first 24 h, mL, (95%CI)	459.9 (225.8-694.0)	698.1 (383.9-1012.3)	0.067
GI bleed, n (%)	1 (20.0)	5 (20.8)	0.948
New VTE, n (%)	4 (20.0)	3 (12.5)	0.635
ICU medications
Volume of IVF (L), (95%CI)	4.02 (2.52-5.53)	4.44 (2.62-6.26)	0.891
Octreotide, n (%)	14 (66.7)	12 (52.2)	0.329
Antibiotics, n (%)	21 (100.0)	24 (100.0)	0.790
Choice of first vasopressor, n (%)
Norepinephrine	18 (85.7)	17 (70.8)	0.412
Dopamine	1 (4.8)	3 (12.5)	0.398
Phenylephrine	2 (9.5)	4 (16.7)	0.207
Albumin given, n (%)	18 (85.7)	21 (95.5)	0.954
PPI, n (%)	18 (90.0)	19 (79.2)	0.388
Corticosteroids, n (%)	16 (76.2)	19 (79.2)	0.701
Outcomes, (95%CI)
Days to death	8.9 (5.2-11.4)	7.8 (4.4-11.1)	0.672
ICU LOS, d	13.5 (8.1-18.8)	12.3 (4.4-20.3)	0.114
Vent free days	22.6 (20.1-25.1)	15.8 (4.1-27.6)	0.633
Mortality, n (%)
7 d	11 (52.4)	14 (58.3)	0.408
28 d	17 (81.0)	21 (87.5)	0.371
90 d	18 (85.7)	21 (87.5)	0.303
In hospital	18 (85.7)	20 (83.3)	0.654
ICU	17 (81.0)	18 (75.0)	0.360
Transition to comfort care	16 (76.2)	18 (75.0)	0.808

CAD: Coronary heart disease; CHF: Congestive heart failure; COPD: Chronic obstructive pulmonary diseases; CKD: Chronic kidney diseases; DM: Diabetes mellitus; HTN: Hypertension; NASH: Non-alcoholic steatohepatitis; HBV: Hepatitis B virus; HCV: Hepatitis C virus; AIH: Autoimmune hepatitis; PSE: Portosystemic encephalopathy; CTP: Child-Turcotte-Pugh score; AST: Aspartate aminotransferase; ALT: Alanine transaminase; BUN: Blood urea nitrogen; WBC: White blood cell; ICU: Intensive care unit; APACHE II: Acute physiology and chronic health evaluation II; SAPSII: Simplified acute physiology score; SOFA: Sequential organ failure assessment; CRRT: Continuous renal replacement therapy; HD: Hemodialysis; GI: Gastrointestinal; PPI: Proton pump inhibitors.

Table 2 Change in laboratory parameters with vasopressor support as measured 24 h after vasopressor initiation

	Vasopressin (n = 21)	No Vasopressin (n = 24)	P value
Platelets, k/uL, (95%CI)	-18.7 (-42.3, 4.9)	-13.6 (-31.6, 4.4)	NS
ALT, U/L, (95%CI)	47.2 (-12.1, 106.6)	206.3 (-113.3, 525.9)	NS
AST, U/L (95%CI)	236.7 (74.0, 399.4)	292.4 (-247.0, 831.8)	NS
Alkaline phosphatase, U/L, (95%CI)	-10.5 (-48.7, 27.8)	-19.6 (-39.5, 0.3)	NS
Heart rate, (95%CI)	-6.7 (-12.3, -1.0)	0.6 (-11.8, 13.0)	NS
Bilirubin, mg/dL, (95%CI)	0.45 (-0.99, 1.89)	0.87 (-0.64, 2.38)	NS

AST: Aspartate aminotransferase; ALT: Alanine transaminase; NS: No statistical significance.

Table 3 Adjusted multivariable analysis for predictors of 28-d all-cause mortality

	Hazard ratio	95%CI	P value
Vasopressin¹	0.77	0.39-1.52	NS
Age (yr)	1.05	1.01-1.08	0.004
CRRT	0.40	0.19-0.85	0.017
Corticosteroids	0.37	0.16-0.86	0.021
Sodium (mmol/L)	1.00	0.96-1.04	NS
Platelets (k/uL)	0.99	0.98-1.00	NS
MELD	1.04	0.98-1.09	NS

¹Compared to reference of non-vasopressin group (P = 0.553). CRRT: Continuous renal replacement therapy; NS: No statistical significance.

Citation: Myc LA, Stine JG, Chakrapani R, Kadl A, Argo CK. Vasopressin use in critically ill cirrhosis patients with catecholamine-resistant septic shock: The CVICU cohort. World J Hepatol 2017; 9(2): 106-113
URL: https://www.wjgnet.com/1948-5182/full/v9/i2/106.htm
DOI: https://dx.doi.org/10.4254/wjh.v9.i2.106